Key facts
- KINS’s last known valuation is $61.9M (Jul 2025).
- It has raised $23.6M; the latest was Later Stage VC ($7.3M) in Jul 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, SBI Investment, Mizuho Capital, Japan Finance Corporation — 26 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for KINS
- ·The full record, as it builds
Funding rounds
No funding rounds for KINS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KINS
Manufacturer of skin care products and supplements intended to maintain the balance of bacteria in the body. The company's products contain various types of lactic acid bacteria, yeast, and lactic acid bacterium and offer food essences, face masks for moisturizing and face serums, and more, enabling customers with holistic health and wellness through microbiome-friendly formulations.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 55
- Website
- yourkins.com/
- Ownership
- Privately Held (backing)
KINS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KINS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KINS in its N-PORT filings yet. We sweep new filings monthly.